TY - JOUR
T1 - BRCAPRO 6.0 model validation in male patients presenting for BRCA testing
AU - Mitri, Zahi I.
AU - Jackson, Michelle
AU - Garby, Carolyn
AU - Song, Juhee
AU - Giordano, Sharon H.
AU - Hortobágyi, Gabriel N.
AU - Singletary, Claire N.
AU - Hashmi, S. Shahrukh
AU - Arun, Banu K.
AU - Litton, Jennifer K.
N1 - Publisher Copyright:
©AlphaMed Press 2015
PY - 2015
Y1 - 2015
N2 - Background. BRCAPRO is a risk assessment model to estimate the risk of carrying a BRCA mutation. BRCA mutation carriers are at higher riskof developing breast, ovarian, pancreatic, and prostate cancer. BRCAPRO was developed for women and found to be superior to other risk assessment models. The present study evaluated the validity of BRCAPRO at predicting the risk of male patients carrying a BRCA mutation. Patients and Methods. A total of 146 men who presented for genetic counseling and testing from February1997 to September 2011, and their test results were included in the present study. BRCAPRO risk assessment for all patients was calculated using the BRCAPRO clinical CancerGene assessment software. Results. The mean age at presentation was 57 years. Of the 146 patients, 48 had breast cancer, 18 had pancreatic cancer, 39 had prostate cancer, 27 had other primary cancers, and 37 had no cancer. Fifty patients (34%) tested positive for a BRCA mutation (22 BRCA1, 27 BRCA2, and 1 BRCA1 and BRCA2).The mean BRCAPRO score for all patients was 24.96%.The BRCAPRO score was significantly higher for patients who tested positive foraBRCA mutation (46.19% vs. 13.9%,p<.01).The area under the receiver operating characteristics curve was 0.83 for all patients for the BRCAPRO score to predict the risk of carrying a BRCA mutation. At a cutoff point of 30.02%, the sensitivity, specificity, positive predictive value, and negative predictive value were 0.74, 0.81, 0.67, and 0.86, respectively. Conclusion. BRCAPRO appears to be a valid risk assessment tool for determining the risk of carrying a BRCA mutation in men. The Oncologist.
AB - Background. BRCAPRO is a risk assessment model to estimate the risk of carrying a BRCA mutation. BRCA mutation carriers are at higher riskof developing breast, ovarian, pancreatic, and prostate cancer. BRCAPRO was developed for women and found to be superior to other risk assessment models. The present study evaluated the validity of BRCAPRO at predicting the risk of male patients carrying a BRCA mutation. Patients and Methods. A total of 146 men who presented for genetic counseling and testing from February1997 to September 2011, and their test results were included in the present study. BRCAPRO risk assessment for all patients was calculated using the BRCAPRO clinical CancerGene assessment software. Results. The mean age at presentation was 57 years. Of the 146 patients, 48 had breast cancer, 18 had pancreatic cancer, 39 had prostate cancer, 27 had other primary cancers, and 37 had no cancer. Fifty patients (34%) tested positive for a BRCA mutation (22 BRCA1, 27 BRCA2, and 1 BRCA1 and BRCA2).The mean BRCAPRO score for all patients was 24.96%.The BRCAPRO score was significantly higher for patients who tested positive foraBRCA mutation (46.19% vs. 13.9%,p<.01).The area under the receiver operating characteristics curve was 0.83 for all patients for the BRCAPRO score to predict the risk of carrying a BRCA mutation. At a cutoff point of 30.02%, the sensitivity, specificity, positive predictive value, and negative predictive value were 0.74, 0.81, 0.67, and 0.86, respectively. Conclusion. BRCAPRO appears to be a valid risk assessment tool for determining the risk of carrying a BRCA mutation in men. The Oncologist.
KW - BRCA
KW - BRCAPRO
KW - Cancer genetics
KW - Genetic counseling
KW - Male breast cancer
KW - Risk models
UR - http://www.scopus.com/inward/record.url?scp=84932615246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84932615246&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2014-0425
DO - 10.1634/theoncologist.2014-0425
M3 - Article
C2 - 25948675
AN - SCOPUS:84932615246
SN - 1083-7159
VL - 20
SP - 593
EP - 597
JO - Oncologist
JF - Oncologist
IS - 6
ER -